Vesey D, Iyer A, Owen E, Kamato D, Johnson D, Gobe G
Front Pharmacol. 2024; 15:1382094.
PMID: 39005931
PMC: 11239397.
DOI: 10.3389/fphar.2024.1382094.
Zhang Y, Zeng J, Bao S, Zhang B, Li X, Wang H
J Thromb Thrombolysis. 2024; 57(6):959-972.
PMID: 38760535
DOI: 10.1007/s11239-024-02993-0.
Paul S, Mukherjee T, Das K
Cancers (Basel). 2024; 16(8).
PMID: 38672649
PMC: 11048528.
DOI: 10.3390/cancers16081568.
Russo V, Falco L, Tessitore V, Mauriello A, Catapano D, Napolitano N
Life (Basel). 2023; 13(9).
PMID: 37763292
PMC: 10532829.
DOI: 10.3390/life13091888.
Pierce D, Buchanan F, Macrae F, Mills J, Cox A, Abualsaoud K
PLoS Pathog. 2023; 19(7):e1011529.
PMID: 37478143
PMC: 10395923.
DOI: 10.1371/journal.ppat.1011529.
Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs.
Xulu K, Augustine T
Pharmaceuticals (Basel). 2022; 15(12).
PMID: 36558983
PMC: 9784118.
DOI: 10.3390/ph15121532.
Elevated risk of thrombotic manifestations of SARS-CoV-2 infection in cancer patients: A literature review.
Stefanile A, Cellerino M, Koudriavtseva T
EXCLI J. 2022; 21:906-920.
PMID: 36172074
PMC: 9489888.
DOI: 10.17179/excli2022-5073.
Pancreatic Proteolytic Enzymes and Cancer: New Support for an Old Theory.
Isaacs L
Integr Cancer Ther. 2022; 21:15347354221096077.
PMID: 35514109
PMC: 9083047.
DOI: 10.1177/15347354221096077.
Small Molecule Compounds of Natural Origin Target Cellular Receptors to Inhibit Cancer Development and Progression.
Wang J, Li D, Zhao B, Kim J, Sui G, Shi J
Int J Mol Sci. 2022; 23(5).
PMID: 35269825
PMC: 8911024.
DOI: 10.3390/ijms23052672.
Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines.
Morais C, Rajandram R, Blakeney J, Iyer A, Suen J, Johnson D
PLoS One. 2021; 16(3):e0248983.
PMID: 33765016
PMC: 7993771.
DOI: 10.1371/journal.pone.0248983.
B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.
Giagulli C, Caccuri F, Zorzan S, Bugatti A, Zani A, Filippini F
Cancer Gene Ther. 2020; 28(6):649-666.
PMID: 33093643
PMC: 8203498.
DOI: 10.1038/s41417-020-00246-9.
Increased expression of protease-activated receptors 2 indicates poor prognosis in HBV related hepatocellular carcinoma.
Chen P, Yang N, Xu L, Zhao F, Zhang M
Infect Agent Cancer. 2019; 14:39.
PMID: 31768188
PMC: 6873753.
DOI: 10.1186/s13027-019-0256-3.
MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.
McAuley J, Bailey K, Ekambaram P, Klei L, Kang H, Hu D
Oncogene. 2019; 38(49):7384-7398.
PMID: 31420608
DOI: 10.1038/s41388-019-0958-4.
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Arce M, Pinto M, Galleguillos M, Munoz C, Lange S, Ramirez C
Cancers (Basel). 2019; 11(8).
PMID: 31382462
PMC: 6721564.
DOI: 10.3390/cancers11081103.
Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.
Gong W, Liu Y, Seidl C, Dreyer T, Drecoll E, Kotzsch M
PLoS One. 2019; 14(2):e0212968.
PMID: 30811511
PMC: 6392272.
DOI: 10.1371/journal.pone.0212968.
PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer.
Tekin C, Shi K, Daalhuisen J, Ten Brink M, Bijlsma M, Spek C
Oncotarget. 2018; 9(62):32010-32023.
PMID: 30174793
PMC: 6112838.
DOI: 10.18632/oncotarget.25880.
Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway.
Zhong W, Chen S, Qin Y, Zhang H, Wang H, Meng J
Oncotarget. 2017; 8(62):104855-104866.
PMID: 29285218
PMC: 5739605.
DOI: 10.18632/oncotarget.20418.
Protease Inhibitors in Tick Saliva: The Role of Serpins and Cystatins in Tick-host-Pathogen Interaction.
Chmelar J, Kotal J, Langhansova H, Kotsyfakis M
Front Cell Infect Microbiol. 2017; 7:216.
PMID: 28611951
PMC: 5447049.
DOI: 10.3389/fcimb.2017.00216.
Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.
Kryza T, Silva L, Bock N, Fuhrman-Luck R, Stephens C, Gao J
Mol Oncol. 2017; 11(10):1307-1329.
PMID: 28510269
PMC: 5623815.
DOI: 10.1002/1878-0261.12075.
Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma.
Li S, Jiang P, Xiang Y, Wang W, Zhu Y, Feng W
Dongwuxue Yanjiu. 2014; 35(5):420-5.
PMID: 25297082
PMC: 4790359.
DOI: 10.13918/j.issn.2095-8137.2014.5.420.